Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · IEX Real-Time Price · USD
0.421
-0.003 (-0.61%)
At close: Apr 26, 2024, 3:59 PM
0.440
+0.019 (4.39%)
After-hours: Apr 26, 2024, 5:57 PM EDT
Cadrenal Therapeutics Stock Forecast
CVKD's stock price has decreased by -70.97% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CVKD stock have an average target of 3.50, with a low estimate of 3.00 and a high estimate of 4.00. The average target predicts an increase of 731.35% from the current stock price of 0.42.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for CVKD stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 | Strong Buy | Reiterates | $3 | +612.59% | Mar 14, 2024 |
| Noble Capital Markets | Noble Capital Markets | Buy Initiates $4 | Buy | Initiates | $4 | +850.12% | Dec 18, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +612.59% | Nov 20, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.35
from -0.62
EPS Next Year
-0.33
from -0.35
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 6.6M | 17.6M |
| Avg | n/a | n/a | n/a | 6.4M | 17.1M |
| Low | n/a | n/a | n/a | 6.2M | 16.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 174.5% |
| Avg | - | - | - | - | 166.7% |
| Low | - | - | - | - | 156.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.23 | -0.23 | -0.22 | -0.81 | -0.58 |
| Avg | -0.35 | -0.33 | -0.33 | -0.79 | -0.56 |
| Low | -0.45 | -0.41 | -0.42 | -0.75 | -0.54 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.